ovarian neoplasms[MeSH] - Search Results

Year	Number of Results
1946	2
1947	1
1948	3
1949	3
1950	1
1951	6
1952	3
1953	4
1954	9
1955	6
1956	6
1957	6
1958	8
1959	7
1960	11
1961	5
1962	8
1963	11
1964	22
1965	18
1966	18
1967	18
1968	13
1969	19
1970	14
1971	27
1972	22
1973	20
1974	30
1975	20
1976	19
1977	12
1978	12
1979	34
1980	21
1981	27
1982	34
1983	39
1984	42
1985	36
1986	44
1987	52
1988	68
1989	69
1990	99
1991	88
1992	107
1993	165
1994	141
1995	160
1996	200
1997	248
1998	210
1999	244
2000	239
2001	238
2002	277
2003	313
2004	349
2005	457
2006	463
2007	524
2008	737
2009	886
2010	926
2011	1118
2012	1256
2013	1321
2014	1505
2015	1600
2016	1657
2017	1627
2018	1609
2019	1834
2020	2017
2021	2009
2022	2070
2023	1869
2024	546

1

TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.

Zhang K, Zheng X, Sun Y, Feng X, Wu X, Liu W, Gao C, Yan Y, Tian W, Wang Y. Zhang K, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2325126. doi: 10.1080/15384047.2024.2325126. Epub 2024 Mar 6. Cancer Biol Ther. 2024. PMID: 38445610 Free PMC article.

2

Causal relationship between affect disorders and endometrial cancer: a Mendelian randomisation study.

Sun Y, Geng S, Fu C, Song X, Lin H, Xu Y. Sun Y, et al. J Obstet Gynaecol. 2024 Dec;44(1):2321321. doi: 10.1080/01443615.2024.2321321. Epub 2024 Feb 29. J Obstet Gynaecol. 2024. PMID: 38425012 Free article.

3

Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion.

Ma J, Li J, Chen X, Ma Y. Ma J, et al. Adipocyte. 2024 Dec;13(1):2282566. doi: 10.1080/21623945.2023.2282566. Epub 2023 Nov 22. Adipocyte. 2024. PMID: 37993991 Free PMC article.

4

Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.

Kallio HM, Savolainen K, Virtanen T, Ryyppö L, Selin H, Martikainen P, Staff S, Kivinummi K, Sipola J, Vuorinen J, Nikkola J, Nykter M, Auranen A, Annala M. Kallio HM, et al. Life Sci Alliance. 2024 Apr 5;7(6):e202402658. doi: 10.26508/lsa.202402658. Print 2024 Jun. Life Sci Alliance. 2024. PMID: 38580393 Free PMC article.

5

Improving the Lives of Women With Ovarian Cancer.

Karlan BY. Karlan BY. Clin Obstet Gynecol. 2024 Jun 1;67(2):347-351. doi: 10.1097/GRF.0000000000000851. Epub 2024 Jan 15. Clin Obstet Gynecol. 2024. PMID: 38230704 Free PMC article.

6

Expression of Concern: Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to upregulate ZEB1 and MDM2.

[No authors listed] [No authors listed] Biosci Rep. 2024 May 29;44(5):BSR-2020-0825_EOC. doi: 10.1042/BSR-2020-0825_EOC. Biosci Rep. 2024. PMID: 38682476 Free article. No abstract available.

7

Screening by Q Exactive liquid chromatography/tandem mass spectrometry identified Choline, 25-hydroxyvitamin D2, and SM(d18:0/16:1(9Z) (OH)) as biomarkers for high-grade serous ovarian cancer.

Li J, Liu D, Cui M, Wei Z. Li J, et al. J Proteomics. 2024 May 15;299:105154. doi: 10.1016/j.jprot.2024.105154. Epub 2024 Mar 11. J Proteomics. 2024. PMID: 38471622 Free article.

8

Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.

Wang Y, Chen X, Chen Q, Liu T, Wu Y, Huang L, Chen Y. Wang Y, et al. J Cell Mol Med. 2024 May;28(9):e18371. doi: 10.1111/jcmm.18371. J Cell Mol Med. 2024. PMID: 38686496 Free PMC article.

9

Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.

Liang H, Geng S, Wang Y, Fang Q, Xin Y, Li Y. Liang H, et al. J Cell Mol Med. 2024 May;28(9):e18315. doi: 10.1111/jcmm.18315. J Cell Mol Med. 2024. PMID: 38680032 Free PMC article.

10

Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer.

Wang L, Xiong B, Lu W, Cheng Y, Zhu J, Ai G, Zhang X, Liu X, Cheng Z. Wang L, et al. Biomed Pharmacother. 2024 May;174:116474. doi: 10.1016/j.biopha.2024.116474. Epub 2024 Mar 21. Biomed Pharmacother. 2024. PMID: 38518604 Free article.

11

PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.

Rausio H, Cervera A, Heuser VD, West G, Oikkonen J, Pianfetti E, Lovino M, Ficarra E, Taimen P, Hynninen J, Lehtonen R, Hautaniemi S, Carpén O, Huhtinen K. Rausio H, et al. Neoplasia. 2024 May;51:100987. doi: 10.1016/j.neo.2024.100987. Epub 2024 Mar 14. Neoplasia. 2024. PMID: 38489912 Free PMC article.

12

Role of circular RNA as competing endogenous RNA in ovarian cancer (Review).

Ye W, Xiang N, Wang Q, Lu Y. Ye W, et al. Int J Mol Med. 2024 May;53(5):41. doi: 10.3892/ijmm.2024.5365. Epub 2024 Mar 8. Int J Mol Med. 2024. PMID: 38456562 Free PMC article. Review.

13

Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.

Ghirardi V, Trozzi R, Scanu FR, Giannarelli D, Santullo F, Costantini B, Naldini A, Panico C, Frassanito L, Scambia G, Fagotti A. Ghirardi V, et al. Ann Surg Oncol. 2024 May;31(5):3350-3360. doi: 10.1245/s10434-024-15042-0. Epub 2024 Feb 27. Ann Surg Oncol. 2024. PMID: 38411761 Free PMC article.

14

Thermoresponsive carboplatin-releasing prodrugs.

McAdam AD, Batchelor LK, Romano-deGea J, Vasilyev D, Dyson PJ. McAdam AD, et al. J Inorg Biochem. 2024 May;254:112505. doi: 10.1016/j.jinorgbio.2024.112505. Epub 2024 Feb 15. J Inorg Biochem. 2024. PMID: 38377623 Free article.

15

The effect of androgens on the risk of endometriosis sub-phenotypes and ovarian neoplasms: A Mendelian randomization study.

Gjorgoska M, Rizner TL. Gjorgoska M, et al. J Steroid Biochem Mol Biol. 2024 May;239:106482. doi: 10.1016/j.jsbmb.2024.106482. Epub 2024 Feb 17. J Steroid Biochem Mol Biol. 2024. PMID: 38369034 Free article.

16

Nutritional interventions during treatment for ovarian cancer: A narrative review and recommendations for future research.

Benna-Doyle S, Baguley BJ, Laing E, Kiss N. Benna-Doyle S, et al. Maturitas. 2024 May;183:107938. doi: 10.1016/j.maturitas.2024.107938. Epub 2024 Feb 10. Maturitas. 2024. PMID: 38367367 Free article. Review.

17

AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.

Monjé N, Dragomir MP, Sinn BV, Hoffmann I, Makhmut A, Simon T, Kunze CA, Ihlow J, Schmitt WD, Pohl J, Piwonski I, Marchenko S, Keunecke C, Calina TG, Tiso F, Kulbe H, Kreuzinger C, Cacsire Castillo-Tong D, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Kübler K, Capper D, Coscia F, Morkel M, Horst D, Sers C, Taube ET. Monjé N, et al. Br J Cancer. 2024 May;130(8):1249-1260. doi: 10.1038/s41416-023-02550-1. Epub 2024 Feb 9. Br J Cancer. 2024. PMID: 38361045 Free PMC article.

18

Parenteral Hydration in Dying Patients With Cancer: A National Registry Study.

Martinsson L, Strang P, Lundström S, Hedman C. Martinsson L, et al. J Pain Symptom Manage. 2024 May;67(5):384-392. doi: 10.1016/j.jpainsymman.2024.01.036. Epub 2024 Feb 9. J Pain Symptom Manage. 2024. PMID: 38342476 Free article.

19

MRI findings of malignant transformation arising from mature cystic teratoma of the ovary: comparison with benign mature cystic teratoma.

Kawaguchi M, Kato H, Furui T, Noda Y, Hyodo F, Miyazaki T, Matsuo M. Kawaguchi M, et al. Jpn J Radiol. 2024 May;42(5):500-507. doi: 10.1007/s11604-023-01521-z. Epub 2023 Dec 26. Jpn J Radiol. 2024. PMID: 38146022 Free PMC article.

20

MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.

Kwon JE, Jang Y, Yun BS, Kang S, Kim YH, Kim BG, Cho NH. Kwon JE, et al. Cell Prolif. 2024 May;57(5):e13582. doi: 10.1111/cpr.13582. Epub 2023 Nov 29. Cell Prolif. 2024. PMID: 38030594 Free PMC article.

21

Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.

Lee Y, Choi S, Kim HS. Lee Y, et al. Int J Gynecol Pathol. 2024 May 1;43(3):221-232. doi: 10.1097/PGP.0000000000000976. Epub 2023 Aug 11. Int J Gynecol Pathol. 2024. PMID: 37566876 Free PMC article.

22

A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.

Zhan F, Guo Y, He L. Zhan F, et al. J Ovarian Res. 2024 Apr 29;17(1):92. doi: 10.1186/s13048-024-01419-y. J Ovarian Res. 2024. PMID: 38685095 Free article.

23

Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.

Cheng Y, Li Q, Sun G, Li T, Zou Y, Ye H, Wang K, Shi J, Wang P. Cheng Y, et al. Sci Rep. 2024 Apr 29;14(1):9757. doi: 10.1038/s41598-024-60544-2. Sci Rep. 2024. PMID: 38684875 Free PMC article.

24

STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).

Liu J, Liu C, Ma Y, Pan X, Chu R, Yao S, Chen J, Liu C, Chen Z, Sheng C, Zhang K, Xue Y, Schiöth HB, Kong B, Zhang Q, Song K. Liu J, et al. Cancer Lett. 2024 Apr 28;588:216700. doi: 10.1016/j.canlet.2024.216700. Epub 2024 Feb 17. Cancer Lett. 2024. PMID: 38373690 Free article.

25

Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.

Andaluz S, Zhao B, Sinha S, Lagniton PNP, Costa DA, Ding X, Brito M, Wang SM. Andaluz S, et al. BMC Genomics. 2024 Apr 27;25(1):416. doi: 10.1186/s12864-024-10311-4. BMC Genomics. 2024. PMID: 38671360 Free PMC article.

26

Laparoscopic transabdominal-sacrococcygeal approach for resection of Altman type III sacrococcygeal teratoma in adult women: A case report.

Zhong Q, Zhang Q, Xiao Z, Zhang H. Zhong Q, et al. Medicine (Baltimore). 2024 Apr 26;103(17):e37887. doi: 10.1097/MD.0000000000037887. Medicine (Baltimore). 2024. PMID: 38669424 Free PMC article.

27

Advances in precision therapy of low-grade serous ovarian cancer: A review.

Wang Q, Cao SH, Li YY, Zhang JB, Yang XH, Zhang B. Wang Q, et al. Medicine (Baltimore). 2024 Apr 26;103(17):e34306. doi: 10.1097/MD.0000000000034306. Medicine (Baltimore). 2024. PMID: 38669365 Free PMC article. Review.

28

The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.

Micek HM, Yang N, Dutta M, Rosenstock L, Ma Y, Hielsberg C, McCord M, Notbohm J, McGregor S, Kreeger PK. Micek HM, et al. Sci Adv. 2024 Apr 26;10(17):eadl4463. doi: 10.1126/sciadv.adl4463. Epub 2024 Apr 26. Sci Adv. 2024. PMID: 38669327 Free PMC article.

29

Hydropic leiomyoma-like ovarian tumor: a case report.

Yamaguchi T, Kyozuka H, Kochi Y, Ito F, Odajima H, Suzuki D, Nomura Y. Yamaguchi T, et al. Fukushima J Med Sci. 2024 Apr 26;70(2):93-98. doi: 10.5387/fms.2023-22. Epub 2024 Mar 15. Fukushima J Med Sci. 2024. PMID: 38494733 Free article.

30

Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.

Nomura S, Watanabe T, Honma R, Matsukura S, Ito E, Imai JI, Kiko Y, Suzuki O, Hashimoto Y, Kojima M, Furukawa S, Soeda S, Watanabe S, Fujimori K. Nomura S, et al. Fukushima J Med Sci. 2024 Apr 26;70(2):65-73. doi: 10.5387/fms.23-00011. Epub 2024 Mar 15. Fukushima J Med Sci. 2024. PMID: 38494731 Free article.

31

Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.

Hu ZL, Yuan YX, Xia MY, Li Y, Yang Y, Wang SN, Meng XZ, Sun MY, Wang N. Hu ZL, et al. J Ovarian Res. 2024 Apr 25;17(1):88. doi: 10.1186/s13048-024-01413-4. J Ovarian Res. 2024. PMID: 38664732 Free PMC article.

32

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition.

Zhang Z, Liu Y, Xu Y, Xu Z, Jia J, Jin Y, Wang W, Liu L. Zhang Z, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):576-585. doi: 10.3724/abbs.2023288. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38433576 Free article.

33

Circular RNA circMAN1A2 promotes ovarian cancer progression through the microRNA-135a-3p/IL1RAP/TAK1 pathway.

Li B, Hu C, Zhao D, Nie M, Wang X. Li B, et al. PeerJ. 2024 Apr 24;12:e16967. doi: 10.7717/peerj.16967. eCollection 2024. PeerJ. 2024. PMID: 38680890 Free PMC article.

34

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.

Böpple K, Oren Y, Henry WS, Dong M, Weller S, Thiel J, Kleih M, Gaißler A, Zipperer D, Kopp HG, Aylon Y, Oren M, Essmann F, Liang C, Aulitzky WE. Böpple K, et al. Cell Death Dis. 2024 Apr 24;15(4):290. doi: 10.1038/s41419-024-06674-x. Cell Death Dis. 2024. PMID: 38658567 Free PMC article.

35

Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.

Sakhri S, Slimane M, Bouaziz H, Khessairi N, Boujelbene N, Ben Dhiab T. Sakhri S, et al. J Med Case Rep. 2024 Apr 24;18(1):217. doi: 10.1186/s13256-024-04476-5. J Med Case Rep. 2024. PMID: 38654310 Free PMC article.

36

Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach.

Beg A, Parveen R, Fouad H, Yahia ME, Hassanein AS. Beg A, et al. J Ovarian Res. 2024 Apr 23;17(1):86. doi: 10.1186/s13048-024-01402-7. J Ovarian Res. 2024. PMID: 38654363 Free PMC article.

37

A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.

Cai X, Lin J, Liu L, Zheng J, Liu Q, Ji L, Sun Y. Cai X, et al. BMC Cancer. 2024 Apr 23;24(1):515. doi: 10.1186/s12885-024-12245-2. BMC Cancer. 2024. PMID: 38654239 Free PMC article.

38

Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis.

Joshi S, López L, Morosi LG, Amadio R, Pachauri M, Bestagno M, Ogar IP, Giacca M, Piperno GM, Vorselen D, Benvenuti F. Joshi S, et al. Cell Rep. 2024 Apr 23;43(4):114096. doi: 10.1016/j.celrep.2024.114096. Epub 2024 Apr 11. Cell Rep. 2024. PMID: 38607919 Free article.

39

Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.

Mishra AK, Ye T, Banday S, Thakare RP, Su CT, Pham NNH, Ali A, Kulshreshtha A, Chowdhury SR, Simone TM, Hu K, Zhu LJ, Eisenhaber B, Deibler SK, Simin K, Thompson PR, Kelliher MA, Eisenhaber F, Malonia SK, Green MR. Mishra AK, et al. Cell Rep. 2024 Apr 23;43(4):114041. doi: 10.1016/j.celrep.2024.114041. Epub 2024 Apr 3. Cell Rep. 2024. PMID: 38573857 Free article.

40

Eating Behaviors and Physical Activity versus the Big Five Personality Traits in Women with a Hereditary Predisposition to Breast or Ovarian Cancer.

Pięta B, Bień A, Pięta M, Żurawska J, Rzymski P, Wilczak M. Pięta B, et al. Nutrients. 2024 Apr 22;16(8):1244. doi: 10.3390/nu16081244. Nutrients. 2024. PMID: 38674934 Free PMC article.

41

Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer-Relation to Tumour Characteristics and Impact on Prognosis.

Stout A, Facey N, Bhatnagar A, Rice K, Berditchevski F, Kearns D, Metcalf A, Elghobashy A, Shaaban AM. Stout A, et al. Int J Mol Sci. 2024 Apr 20;25(8):4524. doi: 10.3390/ijms25084524. Int J Mol Sci. 2024. PMID: 38674108 Free PMC article.

42

Acid-Sensitive Outwardly Rectifying Cl^- Current in OV2944 Mouse Ovarian Cancer Cells.

Hirasawa H, Aoba K, Miwa N. Hirasawa H, et al. Cell Physiol Biochem. 2024 Apr 20;58(2):172-181. doi: 10.33594/000000692. Cell Physiol Biochem. 2024. PMID: 38643508 Free article.

43

A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum.

Dong X, Yuan L, Zou R, Yao L. Dong X, et al. J Ovarian Res. 2024 Apr 19;17(1):85. doi: 10.1186/s13048-024-01401-8. J Ovarian Res. 2024. PMID: 38641834 Free PMC article. Clinical Trial.

44

Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.

de Oliveira Ferreira C, Carneiro VCG, Araujo Mariz C. de Oliveira Ferreira C, et al. BMC Cancer. 2024 Apr 19;24(1):499. doi: 10.1186/s12885-024-12246-1. BMC Cancer. 2024. PMID: 38641594 Free PMC article.

45

Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.

Fu W, Feng Q, Tao R. Fu W, et al. Medicine (Baltimore). 2024 Apr 19;103(16):e37783. doi: 10.1097/MD.0000000000037783. Medicine (Baltimore). 2024. PMID: 38640321 Free PMC article.

46

Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.

Xu AM, Haro M, Walts AE, Hu Y, John J, Karlan BY, Merchant A, Orsulic S. Xu AM, et al. Sci Adv. 2024 Apr 19;10(16):eadk8805. doi: 10.1126/sciadv.adk8805. Epub 2024 Apr 17. Sci Adv. 2024. PMID: 38630822 Free PMC article.

47

Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.

Guo J, Zeng X, Zhu Y, Yang D, Zhao X. Guo J, et al. J Transl Med. 2024 Apr 18;22(1):367. doi: 10.1186/s12967-024-05174-y. J Transl Med. 2024. PMID: 38637885 Free PMC article.

48

ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer.

An Y, Duan H. An Y, et al. J Ovarian Res. 2024 Apr 18;17(1):84. doi: 10.1186/s13048-024-01394-4. J Ovarian Res. 2024. PMID: 38637813 Free PMC article.

49

Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.

Li N, Jin S, Wu J, Ji H, Du C, Liu B. Li N, et al. PLoS One. 2024 Apr 18;19(4):e0299504. doi: 10.1371/journal.pone.0299504. eCollection 2024. PLoS One. 2024. PMID: 38635517 Free PMC article.

50

A Multi-Faceted Analysis Showing CRNDE Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis.

Balcerak A, Szafron LA, Rubel T, Swiderska B, Bonna AM, Konarzewska M, Sołtyszewski I, Kupryjanczyk J, Szafron LM. Balcerak A, et al. Int J Mol Sci. 2024 Apr 16;25(8):4381. doi: 10.3390/ijms25084381. Int J Mol Sci. 2024. PMID: 38673965 Free PMC article.

51

Effects of Resveratrol on In Vivo Ovarian Cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.

Chitcholtan K, Singh M, Tino A, Garrill A, Sykes P. Chitcholtan K, et al. Int J Mol Sci. 2024 Apr 16;25(8):4374. doi: 10.3390/ijms25084374. Int J Mol Sci. 2024. PMID: 38673959 Free PMC article.

52

Comprehensive DNA methylation profiling by MeDIP-NGS identifies potential genes and pathways for epithelial ovarian cancer.

Gautam P, Gupta S, Sachan M. Gautam P, et al. J Ovarian Res. 2024 Apr 16;17(1):83. doi: 10.1186/s13048-024-01395-3. J Ovarian Res. 2024. PMID: 38627856 Free PMC article.

53

Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.

Shen L, Li A, Cui J, Liu H, Zhang S. Shen L, et al. J Ovarian Res. 2024 Apr 16;17(1):82. doi: 10.1186/s13048-024-01399-z. J Ovarian Res. 2024. PMID: 38627854 Free PMC article.

54

Ultrasound-based deep learning radiomics model for differentiating benign, borderline, and malignant ovarian tumours: a multi-class classification exploratory study.

Du Y, Guo W, Xiao Y, Chen H, Yao J, Wu J. Du Y, et al. BMC Med Imaging. 2024 Apr 15;24(1):89. doi: 10.1186/s12880-024-01251-2. BMC Med Imaging. 2024. PMID: 38622546 Free PMC article.

55

A miRNA-7704/IL2RB/AKT feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer.

Meng X, Liang X, Yang S, Wu D, Wang X. Meng X, et al. Exp Cell Res. 2024 Apr 15;437(2):114012. doi: 10.1016/j.yexcr.2024.114012. Epub 2024 Mar 31. Exp Cell Res. 2024. PMID: 38565343 Free article.

56

Exploring the Antiproliferative and Modulatory Effects of 1-Methoxyisobrassinin on Ovarian Cancer Cells: Insights into Cell Cycle Regulation, Apoptosis, Autophagy, and Its Interactions with NAC.

Zigová M, Miškufová V, Budovská M, Michalková R, Mojžiš J. Zigová M, et al. Molecules. 2024 Apr 13;29(8):1773. doi: 10.3390/molecules29081773. Molecules. 2024. PMID: 38675591 Free PMC article.

57

Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.

Steinbuch SC, Lüß AM, Eltrop S, Götte M, Kiesel L. Steinbuch SC, et al. Int J Mol Sci. 2024 Apr 13;25(8):4306. doi: 10.3390/ijms25084306. Int J Mol Sci. 2024. PMID: 38673891 Free PMC article. Review.

58

Stromal cartilage oligomeric matrix protein as a tumorigenic driver in ovarian cancer via Notch3 signaling and epithelial-to-mesenchymal transition.

Gorji-Bahri G, Krishna BM, Hagerling C, Orimo A, Jirström K, Papadakos KS, Blom AM. Gorji-Bahri G, et al. J Transl Med. 2024 Apr 13;22(1):351. doi: 10.1186/s12967-024-05083-0. J Transl Med. 2024. PMID: 38615020 Free PMC article.

59

Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.

Kong D, Wu Y, Liu Q, Huang C, Wang T, Huang Z, Gao Y, Li Y, Guo H. Kong D, et al. Eur J Med Res. 2024 Apr 12;29(1):231. doi: 10.1186/s40001-024-01814-7. Eur J Med Res. 2024. PMID: 38609993 Free PMC article.

60

Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.

Elshami M, Jaber I, Alser M, Al-Slaibi I, Jabr H, Ubaiat S, Tuffaha A, Khader S, Khraishi R, Arafeh ZA, Al-Madhoun S, Alqattaa A, Yaseen A, El Hadi AA, Barhoush O, Hijazy M, Eleyan T, Alser A, Hziema AA, Shatat A, Almakhtoob F, Mohamad B, Farhat W, Abuamra Y, Mousa H, Adawi R, Musallam A, Albarqi SI, Abu-El-Noor N, Bottcher B. Elshami M, et al. BMC Public Health. 2024 Apr 12;24(1):1027. doi: 10.1186/s12889-024-18437-6. BMC Public Health. 2024. PMID: 38609950 Free PMC article.

61

Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.

Tran TM, Chand Thakuri BK, Nurmukhambetova S, Lee JJ, Hu P, Tran NQ, Steimle B, Dash P, Schneider D. Tran TM, et al. J Immunother Cancer. 2024 Apr 12;12(4):e008261. doi: 10.1136/jitc-2023-008261. J Immunother Cancer. 2024. PMID: 38609317 Free PMC article.

62

Cellular Imaging and Time-Domain FLIM Studies of Meso-Tetraphenylporphine Disulfonate as a Photosensitising Agent in 2D and 3D Models.

Balukova A, Bokea K, Barber PR, Ameer-Beg SM, MacRobert AJ, Yaghini E. Balukova A, et al. Int J Mol Sci. 2024 Apr 11;25(8):4222. doi: 10.3390/ijms25084222. Int J Mol Sci. 2024. PMID: 38673807 Free PMC article.

63

Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S. Casey NP, et al. J Immunother Cancer. 2024 Apr 11;12(4):e008179. doi: 10.1136/jitc-2023-008179. J Immunother Cancer. 2024. PMID: 38604812 Free PMC article.

64

Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.

Chen Z, Wang C, Ding J, Yu T, Li N, Ye C. Chen Z, et al. PLoS One. 2024 Apr 11;19(4):e0291149. doi: 10.1371/journal.pone.0291149. eCollection 2024. PLoS One. 2024. PMID: 38603733 Free PMC article.

65

Copper(II) Complexes with 2,2':6',2″-Terpyridine Derivatives Displaying Dimeric Dichloro-μ-Bridged Crystal Structure: Biological Activities from 2D and 3D Tumor Spheroids to In Vivo Models.

Choroba K, Machura B, Erfurt K, Casimiro AR, Cordeiro S, Baptista PV, Fernandes AR. Choroba K, et al. J Med Chem. 2024 Apr 11;67(7):5813-5836. doi: 10.1021/acs.jmedchem.4c00119. Epub 2024 Mar 22. J Med Chem. 2024. PMID: 38518246 Free PMC article.

66

Genetically identification of endometriosis and cancers risk in women through a two-sample Mendelian randomization study.

Zhang L, Yan H. Zhang L, et al. Sci Rep. 2024 Apr 10;14(1):8382. doi: 10.1038/s41598-024-58950-7. Sci Rep. 2024. PMID: 38600147 Free PMC article.

67

NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.

Ghini V, Sorbi F, Fambrini M, Magherini F. Ghini V, et al. Cells. 2024 Apr 9;13(8):661. doi: 10.3390/cells13080661. Cells. 2024. PMID: 38667276 Free PMC article.

68

Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.

Bhaskari J, Bhagat R, Shilpa V, Premalata CS, Krishnamoorthy L. Bhaskari J, et al. J Ovarian Res. 2024 Apr 9;17(1):77. doi: 10.1186/s13048-024-01398-0. J Ovarian Res. 2024. PMID: 38594780 Free PMC article.

69

Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.

Du Y, Xiao Y, Guo W, Yao J, Lan T, Li S, Wen H, Zhu W, He G, Zheng H, Chen H. Du Y, et al. Biomed Eng Online. 2024 Apr 9;23(1):41. doi: 10.1186/s12938-024-01234-y. Biomed Eng Online. 2024. PMID: 38594729 Free PMC article. Clinical Trial.

70

Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.

Motonari T, Yoshino Y, Haruta M, Endo S, Sasaki S, Miyashita M, Tada H, Watanabe G, Kaneko T, Ishida T, Chiba N. Motonari T, et al. Sci Rep. 2024 Apr 8;14(1):7519. doi: 10.1038/s41598-024-57367-6. Sci Rep. 2024. PMID: 38589490 Free PMC article.

71

Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression.

Zhao L, Huang J, Liu W, Su X, Zhao B, Wang X, He X. Zhao L, et al. J Cancer Res Clin Oncol. 2024 Apr 7;150(4):179. doi: 10.1007/s00432-024-05671-z. J Cancer Res Clin Oncol. 2024. PMID: 38584230 Free PMC article.

72

Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.

Hrvat A, Benders S, Kimmig R, Brandau S, Mallmann-Gottschalk N. Hrvat A, et al. Front Immunol. 2024 Apr 5;15:1360615. doi: 10.3389/fimmu.2024.1360615. eCollection 2024. Front Immunol. 2024. PMID: 38646521 Free PMC article.

73

The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

Lashen A, Algethami M, Alqahtani S, Shoqafi A, Sheha A, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S. Lashen A, et al. Int J Mol Sci. 2024 Apr 5;25(7):4060. doi: 10.3390/ijms25074060. Int J Mol Sci. 2024. PMID: 38612869 Free PMC article.

74

Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.

Kim YN, Chung YS, Park E, Lee ST, Lee JY. Kim YN, et al. Sci Rep. 2024 Apr 5;14(1):7992. doi: 10.1038/s41598-024-57515-y. Sci Rep. 2024. PMID: 38580676 Free PMC article.

75

Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.

Martincuks A, Zhang C, Austria T, Li YJ, Huang R, Lugo Santiago N, Kohut A, Zhao Q, Borrero RM, Shen B, Cristea M, Wang EW, Song M, Rodriguez-Rodriguez L, Yu H. Martincuks A, et al. J Immunother Cancer. 2024 Apr 5;12(4):e007716. doi: 10.1136/jitc-2023-007716. J Immunother Cancer. 2024. PMID: 38580335 Free PMC article.

76

Ginger inhibits the invasion of ovarian cancer cells SKOV3 through CLDN7, CLDN11 and CD274 m6A methylation modifications.

Zhang X, Zhang H, Zhu L, Xia L. Zhang X, et al. BMC Complement Med Ther. 2024 Apr 4;24(1):145. doi: 10.1186/s12906-024-04431-3. BMC Complement Med Ther. 2024. PMID: 38575994 Free PMC article.

77

Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells.

Islam SS, Al-Mohanna FH, Yousef IM, Al-Badawi IA, Aboussekhra A. Islam SS, et al. Cell Death Dis. 2024 Apr 4;15(4):247. doi: 10.1038/s41419-024-06512-0. Cell Death Dis. 2024. PMID: 38575576 Free PMC article.

78

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Mehra T, Lupatsch JE, Kössler T, Dedes K, Siebenhüner AR, von Moos R, Wicki A, Schwenkglenks ME. Mehra T, et al. PLoS One. 2024 Apr 4;19(4):e0301271. doi: 10.1371/journal.pone.0301271. eCollection 2024. PLoS One. 2024. PMID: 38573891 Free PMC article.

79

Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.

Denisenko E, de Kock L, Tan A, Beasley AB, Beilin M, Jones ME, Hou R, Muirí DÓ, Bilic S, Mohan GRKA, Salfinger S, Fox S, Hmon KPW, Yeow Y, Kim Y, John R, Gilderman TS, Killingbeck E, Gray ES, Cohen PA, Yu Y, Forrest ARR. Denisenko E, et al. Nat Commun. 2024 Apr 3;15(1):2860. doi: 10.1038/s41467-024-47271-y. Nat Commun. 2024. PMID: 38570491 Free PMC article.

80

High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment.

Vivod G, Merlo S, Kovacevic N. Vivod G, et al. Curr Oncol. 2024 Apr 2;31(4):1920-1935. doi: 10.3390/curroncol31040144. Curr Oncol. 2024. PMID: 38668047 Free PMC article. Review.

81

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.

Al-Alem L, Prendergast JM, Clark J, Zarrella B, Zarrella DT, Hill SJ, Growdon WB, Pooladanda V, Spriggs DR, Cramer D, Elias KM, Nazer RI, Skates SJ, Behrens J, Dransfield DT, Rueda BR. Al-Alem L, et al. J Ovarian Res. 2024 Apr 2;17(1):71. doi: 10.1186/s13048-024-01397-1. J Ovarian Res. 2024. PMID: 38566237 Free PMC article.

82

Stearoyl-CoA desaturase 1 inhibition induces ER stress-mediated apoptosis in ovarian cancer cells.

Lee J, Jang S, Im J, Han Y, Kim S, Jo H, Wang W, Cho U, Kim SI, Seol A, Kim B, Song YS. Lee J, et al. J Ovarian Res. 2024 Apr 2;17(1):73. doi: 10.1186/s13048-024-01389-1. J Ovarian Res. 2024. PMID: 38566208 Free PMC article.

83

Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.

Nie H, Saini P, Miyamoto T, Liao L, Zielinski RJ, Liu H, Zhou W, Wang C, Murphy B, Towers M, Yang T, Qi Y, Kannan T, Kossenkov A, Tateno H, Claiborne DT, Zhang N, Abdel-Mohsen M, Zhang R. Nie H, et al. Nat Commun. 2024 Apr 2;15(1):2853. doi: 10.1038/s41467-024-47069-y. Nat Commun. 2024. PMID: 38565883 Free PMC article.

84

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.

Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramon Y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sánchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, Balmaña J. Torres-Esquius S, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247811. doi: 10.1001/jamanetworkopen.2024.7811. JAMA Netw Open. 2024. PMID: 38648056 Free PMC article.

85

Ovarian serous carcinoma with stomach metastasis: a rare case report and literature review.

Hu JL, Guo ZJ, Wang C, Yan J, Yang H. Hu JL, et al. J Int Med Res. 2024 Apr;52(4):3000605241245000. doi: 10.1177/03000605241245000. J Int Med Res. 2024. PMID: 38635893 Free PMC article. Review.

86

Human tumour vessel heterogeneity in ovarian cancer and its association with response to neoadjuvant chemotherapy.

Gabriel EM, Sukniam K, Popp K, Kowkabany G, Manaise HK, Attwood K, George A, Zhai Q, Bagaria SP, Knutson KL, Skitzki JJ, Robertson MW, Dinh TA. Gabriel EM, et al. Clin Transl Med. 2024 Apr;14(4):e1633. doi: 10.1002/ctm2.1633. Clin Transl Med. 2024. PMID: 38616706 Free PMC article. No abstract available.

87

Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.

Sun W, Xu P, Gao K, Lian W, Sun X. Sun W, et al. J Cell Mol Med. 2024 Apr;28(8):e18309. doi: 10.1111/jcmm.18309. J Cell Mol Med. 2024. PMID: 38613345 Free PMC article.

88

Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma.

Guo QH, Xie FC, Zhong FM, Wen W, Zhang XR, Yu XJ, Wang XL, Huang B, Li LP, Wang XZ. Guo QH, et al. Cancer Med. 2024 Apr;13(7):e7161. doi: 10.1002/cam4.7161. Cancer Med. 2024. PMID: 38613173 Free PMC article.

89

Outcomes after fertility-sparing surgery of early-stage ovarian cancer: A nationwide population-based study.

Lee CY, Chiang CJ, Tai YJ, Hsu HC, Chen YL, Chiang YC, Wu CY, Lee WC, Hwa HL, Cheng WF. Lee CY, et al. Cancer Med. 2024 Apr;13(7):e7132. doi: 10.1002/cam4.7132. Cancer Med. 2024. PMID: 38606892 Free PMC article.

90

Bayesian and deep-learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers.

Abrego L, Zaikin A, Marino IP, Krivonosov MI, Jacobs I, Menon U, Gentry-Maharaj A, Blyuss O. Abrego L, et al. Cancer Med. 2024 Apr;13(7):e7163. doi: 10.1002/cam4.7163. Cancer Med. 2024. PMID: 38597129 Free PMC article.

91

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.

Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, Ernst C, Treilleux I, Medioni J, Heitz F, Pisano C, Garcia Y, Petru E, Hietanen S, Colombo N, Vergote I, Nagao S, Linn SC, Pujade-Lauraine E, Ray-Coquard I, Harter P, Hahnen E, Schmutzler RK. Schouten PC, et al. JAMA Netw Open. 2024 Apr 1;7(4):e245552. doi: 10.1001/jamanetworkopen.2024.5552. JAMA Netw Open. 2024. PMID: 38592722 Free PMC article. Clinical Trial.

92

Neonatal juvenile granulosa cell tumour, a rare entity.

Borrás Mullor B, Navio Anaya M, Conca Baenes MA, Porcar Almela M. Borrás Mullor B, et al. An Pediatr (Engl Ed). 2024 Apr;100(4):e8-e9. doi: 10.1016/j.anpede.2024.03.033. Epub 2024 Apr 4. An Pediatr (Engl Ed). 2024. PMID: 38575475 Free article. No abstract available.

93

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.

Uekusa R, Yokoi A, Watanabe E, Yoshida K, Yoshihara M, Tamauchi S, Shimizu Y, Ikeda Y, Yoshikawa N, Niimi K, Suzuki S, Kajiyama H. Uekusa R, et al. Cancer Med. 2024 Apr;13(7):e7149. doi: 10.1002/cam4.7149. Cancer Med. 2024. PMID: 38572951 Free PMC article.

94

Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells.

Neuhaus F, Lieber S, Shinkevich V, Steitz AM, Raifer H, Roth K, Finkernagel F, Worzfeld T, Burchert A, Keber C, Nist A, Stiewe T, Reinartz S, Beutgen VM, Graumann J, Pauck K, Garn H, Gaida M, Müller R, Huber M. Neuhaus F, et al. Clin Transl Med. 2024 Apr;14(4):e1604. doi: 10.1002/ctm2.1604. Clin Transl Med. 2024. PMID: 38566518 Free PMC article.

95

Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.

Yuan H, Li N, Wu L, Yao H. Yuan H, et al. J Ovarian Res. 2024 Apr 1;17(1):70. doi: 10.1186/s13048-024-01400-9. J Ovarian Res. 2024. PMID: 38561819 Free PMC article.

96

PMFFNet: A hybrid network based on feature pyramid for ovarian tumor segmentation.

Li L, He L, Guo W, Ma J, Sun G, Ma H. Li L, et al. PLoS One. 2024 Apr 1;19(4):e0299360. doi: 10.1371/journal.pone.0299360. eCollection 2024. PLoS One. 2024. PMID: 38557660 Free PMC article.

97

A longitudinal study of symptom cluster latent profiles in ovarian cancer patients undergoing chemotherapy.

Feng Y, Lin T, Liu X, Guo X, Chen J, Deng X. Feng Y, et al. Cancer Med. 2024 Apr;13(7):e7139. doi: 10.1002/cam4.7139. Cancer Med. 2024. PMID: 38545759 Free PMC article.

98

Prognostic and immunotherapeutic potential of regulatory T cell-associated signature in ovarian cancer.

Liu Y, Shan F, Sun Y, Kai H, Cao Y, Huang M, Liu J, Zhang P, Zheng Y. Liu Y, et al. J Cell Mol Med. 2024 Apr;28(8):e18248. doi: 10.1111/jcmm.18248. J Cell Mol Med. 2024. PMID: 38520220 Free PMC article.

99

Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.

Xiong J, Liang H, Sun X, Gao K. Xiong J, et al. J Cell Mol Med. 2024 Apr;28(8):e18260. doi: 10.1111/jcmm.18260. J Cell Mol Med. 2024. PMID: 38520216 Free PMC article.

100

Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer.

Gao L, Wei Z, Ying F, Huang L, Zhang J, Sun S, Wang Z, Cai J, Zhang Y. Gao L, et al. J Cell Mol Med. 2024 Apr;28(7):e18198. doi: 10.1111/jcmm.18198. J Cell Mol Med. 2024. PMID: 38506093 Free PMC article.

101

Exploiting Co(III)-Cyclopentadienyl Complexes To Develop Anticancer Agents.

Franco Machado J, Cordeiro S, Duarte JN, Costa PJ, Mendes PJ, Garcia MH, Baptista PV, Fernandes AR, Morais TS. Franco Machado J, et al. Inorg Chem. 2024 Apr 1;63(13):5783-5804. doi: 10.1021/acs.inorgchem.3c03696. Epub 2024 Mar 19. Inorg Chem. 2024. PMID: 38502532 Free PMC article.

102

A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors.

Nomani A, Yousefi S, Sargsyan D, Hatefi A. Nomani A, et al. J Control Release. 2024 Apr;368:728-739. doi: 10.1016/j.jconrel.2024.03.019. Epub 2024 Mar 19. J Control Release. 2024. PMID: 38493951 Free article.

103

Dipeptide-catalysed Michael reaction under physiological conditions: Examination of potential bioorthogonality.

Schuster F, Grau BW, Xu HG, Mokhir A, Tsogoeva SB. Schuster F, et al. Bioorg Med Chem. 2024 Apr 1;103:117650. doi: 10.1016/j.bmc.2024.117650. Epub 2024 Feb 22. Bioorg Med Chem. 2024. PMID: 38492540 Free article.

104

A rare case of tumor-to-tumor metastasis from thymic carcinoma to an ovarian mature teratoma.

Sasada T, Shirakawa C, Tachikawa R, Yamashita D, Tomii K. Sasada T, et al. Thorac Cancer. 2024 Apr;15(11):934-937. doi: 10.1111/1759-7714.15277. Epub 2024 Mar 11. Thorac Cancer. 2024. PMID: 38468427 Free PMC article.

105

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

Ottenbourgs T, van Gorp T, Kridelka F, Baert T, Denys H, Selle F, Baas I, Van Rompuy AS, Lambrechts D, Van Nieuwenhuysen E. Ottenbourgs T, et al. Int J Gynecol Cancer. 2024 Apr 1;34(4):627-630. doi: 10.1136/ijgc-2023-005189. Int J Gynecol Cancer. 2024. PMID: 38453176 Free PMC article. Clinical Trial.

106

The detailed histopathological characteristics of ovarian fibroma compared with thecoma, granulosa cell tumor, and sclerosing stromal tumor.

Mobarki M, Papoudou-Bai A, Musawi S, Péoc'h M, Karpathiou G. Mobarki M, et al. Pathol Res Pract. 2024 Apr;256:155236. doi: 10.1016/j.prp.2024.155236. Epub 2024 Mar 2. Pathol Res Pract. 2024. PMID: 38447489 Free article.

107

Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/ABCG2 in epithelial ovarian cancer.

Chen S, Liu Z, Wu H, Wang B, Ouyang Y, Liu J, Zheng X, Zhang H, Li X, Feng X, Li Y, Shen Y, Zhang H, Xiao B, Yu C, Deng W. Chen S, et al. Int J Mol Med. 2024 Apr;53(4):37. doi: 10.3892/ijmm.2024.5361. Epub 2024 Mar 1. Int J Mol Med. 2024. PMID: 38426604 Free PMC article.

108

FoxO1 promotes ovarian cancer by increasing transcription and METTL14-mediated m⁶A modification of SMC4.

Tan L, Wang S, Huang S, Tie Y, Sai N, Mao Y, Zhao S, Hou Y, Dou H. Tan L, et al. Cancer Sci. 2024 Apr;115(4):1224-1240. doi: 10.1111/cas.16120. Epub 2024 Feb 25. Cancer Sci. 2024. PMID: 38403332 Free PMC article.

109

MR diagnosis of SCC arising within ovarian cystic teratomas: analysis of mural nodule characteristics.

Fukuzawa T, Ohya A, Tanaka M, Shimizu M, Kobayashi K, Matsushita T, Watanabe T, Kobara H, Fujinaga Y. Fukuzawa T, et al. Abdom Radiol (NY). 2024 Apr;49(4):1264-1274. doi: 10.1007/s00261-024-04186-y. Epub 2024 Feb 23. Abdom Radiol (NY). 2024. PMID: 38393356 Free PMC article.

110

FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.

Miao H, Meng H, Zhang Y, Chen T, Zhang L, Cheng W. Miao H, et al. Cell Death Differ. 2024 Apr;31(4):497-510. doi: 10.1038/s41418-024-01263-z. Epub 2024 Feb 19. Cell Death Differ. 2024. PMID: 38374229 Free PMC article.

111

Hepatitis E virus causes apoptosis of ovarian cells in hens and resulting in a decrease in egg production.

Zhang Y, Gao X, Cao M, Xu H, Liu H, Zhao Q, Zhou EM, Chen Y, Liu B. Zhang Y, et al. Poult Sci. 2024 Apr;103(4):103501. doi: 10.1016/j.psj.2024.103501. Epub 2024 Jan 26. Poult Sci. 2024. PMID: 38350386 Free PMC article.

112

Splicing Factor PQBP1 Curtails BAX Expression to Promote Ovarian Cancer Progression.

Liu X, Zhang J, Wang Z, Yan M, Xu M, Li G, Shender V, Wei JJ, Li J, Shao C, Zhang S, Kong B, Song K, Liu Z. Liu X, et al. Adv Sci (Weinh). 2024 Apr;11(15):e2306229. doi: 10.1002/advs.202306229. Epub 2024 Feb 11. Adv Sci (Weinh). 2024. PMID: 38342602 Free PMC article.

113

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy.

Rognoni C, Lorusso D, Costa F, Armeni P. Rognoni C, et al. Adv Ther. 2024 Apr;41(4):1385-1400. doi: 10.1007/s12325-024-02791-3. Epub 2024 Feb 8. Adv Ther. 2024. PMID: 38329713 Free PMC article.

114

Therapeutic management of uterine tumours resembling ovarian sex cord tumours including a focus on fertility: A systematic review.

Shibahara M, Kurita T, Harada H, Tsuda Y, Hisaoka M, Yoshino K. Shibahara M, et al. Eur J Obstet Gynecol Reprod Biol. 2024 Apr;295:1-7. doi: 10.1016/j.ejogrb.2024.01.039. Epub 2024 Feb 1. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38310674 Free article. Review.

115

Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions.

Chien YW, Wang Y, Huang P, Lawson BC, Kolin DL, Chui MH, Vang R, Numan TA, Soong TR, Wang BG, Smith SA, Chen CL, Stone R, Douville C, Wang TL, Shih IM. Chien YW, et al. Am J Surg Pathol. 2024 Apr 1;48(4):475-486. doi: 10.1097/PAS.0000000000002187. Epub 2024 Feb 1. Am J Surg Pathol. 2024. PMID: 38298022 Free PMC article.

116

Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.

Zhang X, Liao X, Wang M, Liu J, Han J, An D, Zheng T, Wang X, Cheng H, Liu P. Zhang X, et al. Cancer Sci. 2024 Apr;115(4):1170-1183. doi: 10.1111/cas.16085. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287874 Free PMC article.

117

Nanoparticle Targeting in Chemo-Resistant Ovarian Cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.

Wang Y, Calvert AE, Cardenas H, Rink JS, Nahotko D, Qiang W, Ndukwe CE, Chen F, Keathley R, Zhang Y, Cheng JX, Thaxton CS, Matei D. Wang Y, et al. Adv Sci (Weinh). 2024 Apr;11(13):e2305212. doi: 10.1002/advs.202305212. Epub 2024 Jan 23. Adv Sci (Weinh). 2024. PMID: 38263873 Free PMC article.

118

Endometrioid adenocarcinoma caused by adenomyosis: A case report.

Chen YH, Zhou Y, Xue M, Sun L. Chen YH, et al. Asian J Surg. 2024 Apr;47(4):1921-1922. doi: 10.1016/j.asjsur.2023.11.091. Epub 2024 Jan 23. Asian J Surg. 2024. PMID: 38262788 Free article. No abstract available.

119

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.

Nicum S, McGregor N, Austin R, Collins L, Dutton S, McNeish I, Glasspool R, Hall M, Roux R, Michael A, Clamp A, Jayson G, Kristeleit R, Banerjee S, Mansouri A. Nicum S, et al. Br J Cancer. 2024 Apr;130(6):941-950. doi: 10.1038/s41416-023-02567-6. Epub 2024 Jan 20. Br J Cancer. 2024. PMID: 38245661 Free PMC article. Clinical Trial.

120

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.

Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, Traina TA, Anders C, Yeong J, Renzulli E, Kim SB, Dent R. Tan TJ, et al. Clin Cancer Res. 2024 Apr 1;30(7):1240-1247. doi: 10.1158/1078-0432.CCR-23-2513. Clin Cancer Res. 2024. PMID: 38236575 Free PMC article. Clinical Trial.

121

Gynecological cancer during pregnancy-From a gyne-oncological perspective.

Bohlin KS, Brännström M, Dahm-Kähler P. Bohlin KS, et al. Acta Obstet Gynecol Scand. 2024 Apr;103(4):761-766. doi: 10.1111/aogs.14763. Epub 2024 Jan 6. Acta Obstet Gynecol Scand. 2024. PMID: 38183316 Free PMC article.

122

Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.

Zhang Q, Guo F, Liu H, Hong L. Zhang Q, et al. Int Wound J. 2024 Apr;21(4):e14569. doi: 10.1111/iwj.14569. Epub 2023 Dec 29. Int Wound J. 2024. PMID: 38158767 Free PMC article.

123

Effect of bevacizumab in combination with chemotherapy for ovarian cancer on wound healing in patients: A meta-analysis.

Xue Y, Zhao F. Xue Y, et al. Int Wound J. 2024 Apr;21(4):e14531. doi: 10.1111/iwj.14531. Epub 2023 Dec 27. Int Wound J. 2024. PMID: 38151891 Free PMC article. Review.

124

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Lorusso D, et al. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. Int J Gynecol Cancer. 2024. PMID: 38129136 Free PMC article. Clinical Trial.

125

Impact of obese patients in ovarian cancer surgery on postoperative wound complications: A meta-analysis.

Huang X, Du S, Wang Q, Yang C, Liu X, Chen K, Zhao Y, He N, Wang H. Huang X, et al. Int Wound J. 2024 Apr;21(4):e14439. doi: 10.1111/iwj.14439. Epub 2023 Dec 8. Int Wound J. 2024. PMID: 38064172 Free PMC article.

126

Imaging PARP Upregulation with [¹²³I]I-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma.

Ndlovu H, Lawal I, Mokoala K, Disenyane D, Nkambule N, Bassa S, Mzizi Y, Bida M, Sathekge M. Ndlovu H, et al. J Nucl Med. 2024 Apr 1;65(4):665-666. doi: 10.2967/jnumed.123.266348. J Nucl Med. 2024. PMID: 38050115 Free PMC article. No abstract available.

127

Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.

Baglini E, Chiaverini L, Tolbatov I, Taliani S, Da Settimo F, La Mendola D, Barresi E, Marzo T. Baglini E, et al. Biometals. 2024 Apr;37(2):275-288. doi: 10.1007/s10534-023-00547-0. Epub 2023 Nov 6. Biometals. 2024. PMID: 37930483 Free PMC article. Review.

128

Does controlled ovarian hyperstimulation in women with a history of borderline tumor influence recurrence rate?

Gao H, Wei W, Li Y, Wei H, Wang N. Gao H, et al. Arch Gynecol Obstet. 2024 Apr;309(4):1515-1523. doi: 10.1007/s00404-023-07103-8. Epub 2023 Sep 26. Arch Gynecol Obstet. 2024. PMID: 37750934 Free PMC article.

129

Imaging features, clinical characteristics and neonatal outcomes of pregnancy luteoma: A case series and literature review.

Shang JH, Huang CX, Zheng Q, Feng JL, He K, Xie HN. Shang JH, et al. Acta Obstet Gynecol Scand. 2024 Apr;103(4):740-750. doi: 10.1111/aogs.14672. Epub 2023 Sep 14. Acta Obstet Gynecol Scand. 2024. PMID: 37710408 Free PMC article. Review.

130

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.

Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, Torres-Esquius S, Balmaña J, Lázaro C, Brunet JM, Barretina-Ginesta MP. Pla-Juher H, et al. Clin Transl Oncol. 2024 Apr;26(4):1033-1037. doi: 10.1007/s12094-023-03312-4. Epub 2023 Sep 8. Clin Transl Oncol. 2024. PMID: 37682500 Free PMC article.

131

Shedding Light on the Interaction Between Rif1 and Telomeres in Ovarian Cancer.

Kordowitzki P, Graczyk S, Mechsner S, Sehouli J. Kordowitzki P, et al. Aging Dis. 2024 Apr 1;15(2):535-545. doi: 10.14336/AD.2023.0716. Aging Dis. 2024. PMID: 37548940 Free PMC article. Review.

132

Unusual presentation of jejunal adenocarcinoma and ovarian metastasis.

García García MD, Galván Fernández MD, Mouhtar El Halabi SA, Machuca Aguado J, Argüelles-Arias F. García García MD, et al. Rev Esp Enferm Dig. 2024 Apr;116(4):225-226. doi: 10.17235/reed.2023.9658/2023. Rev Esp Enferm Dig. 2024. PMID: 37170586 Free article.

133

Unique Case of Rare Non-Neural Granular Cell Tumor of the Rectus Abdominis Muscle.

Kiskinov PI, Palavurov AM, Mollova-Kyosebekirova AY, Atliev KT, Zanzov EI, Anastasova VN. Kiskinov PI, et al. Medicina (Kaunas). 2024 Mar 31;60(4):576. doi: 10.3390/medicina60040576. Medicina (Kaunas). 2024. PMID: 38674222 Free PMC article.

134

Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.

Frezzini S, Lonardi S. Frezzini S, et al. Cells. 2024 Mar 31;13(7):611. doi: 10.3390/cells13070611. Cells. 2024. PMID: 38607050 Free PMC article. Review.

135

Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.

Jin X, Chen Y, Hu Q. Jin X, et al. Sci Rep. 2024 Mar 31;14(1):7593. doi: 10.1038/s41598-024-57946-7. Sci Rep. 2024. PMID: 38556590 Free PMC article.

136

Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.

Pongratanakul P, Bremmer F, Pauls S, Poschmann G, Kresbach C, Parmaksiz F, Skowron MA, Fuß J, Stephan A, Paffenholz P, Stühler K, Schüller U, Ströbel P, Heidenreich A, Che Y, Albers P, Nettersheim D. Pongratanakul P, et al. Cancer Lett. 2024 Mar 31;585:216673. doi: 10.1016/j.canlet.2024.216673. Epub 2024 Jan 29. Cancer Lett. 2024. PMID: 38296184 Free article.

137

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.

Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. Giudice E, et al. Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6. Nat Commun. 2024. PMID: 38555285 Free PMC article. Clinical Trial.

138

Novel (±)-trans-β-lactam ureas: Synthesis, in silico and in vitro biological profiling.

Jurin M, Stepanić V, Bojanić K, Vadlja D, Kontrec D, Dražić T, Roje M. Jurin M, et al. Acta Pharm. 2024 Mar 30;74(1):37-59. doi: 10.2478/acph-2024-0008. Print 2024 Mar 1. Acta Pharm. 2024. PMID: 38554382 Free article.

139

Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.

Wilkinson AN, Chen R, Coleborn E, Neilson T, Le K, Bhavsar C, Wang Y, Atluri S, Irgam G, Wong K, Yang D, Steptoe R, Wu SY. Wilkinson AN, et al. Cancer Immunol Immunother. 2024 Mar 30;73(5):80. doi: 10.1007/s00262-024-03674-w. Cancer Immunol Immunother. 2024. PMID: 38554167 Free PMC article.

140

Podocalyxin promotes the formation of compact and chemoresistant cancer spheroids in high grade serous carcinoma.

Le Tran N, Wang Y, Bilandzic M, Stephens A, Nie G. Le Tran N, et al. Sci Rep. 2024 Mar 30;14(1):7539. doi: 10.1038/s41598-024-57053-7. Sci Rep. 2024. PMID: 38553472 Free PMC article.

141

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance.

Suzuki T, Conant A, Jung Y, Bax R, Antonissen A, Chen W, Yu G, Ioffe YJ, Wang C, Unternaehrer JJ. Suzuki T, et al. Int J Mol Sci. 2024 Mar 29;25(7):3843. doi: 10.3390/ijms25073843. Int J Mol Sci. 2024. PMID: 38612653 Free PMC article.

142

Associations between gut microbiota and gynecological cancers: A bi-directional two-sample Mendelian randomization study.

Kong Y, Liu S, Wang X, Qie R. Kong Y, et al. Medicine (Baltimore). 2024 Mar 29;103(13):e37628. doi: 10.1097/MD.0000000000037628. Medicine (Baltimore). 2024. PMID: 38552081 Free PMC article.

143

Single-cell transcriptomics reveals comprehensive microenvironment and highlights the dysfuntional state of NK cells in endometrioid carcinoma.

Shi W, Wu W, Wang J, Meng X. Shi W, et al. Medicine (Baltimore). 2024 Mar 29;103(13):e37555. doi: 10.1097/MD.0000000000037555. Medicine (Baltimore). 2024. PMID: 38552055 Free PMC article.

144

MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Flores-Colón M, Rivera-Serrano M, Reyes-Burgos VG, Rolón JG, Pérez-Santiago J, Marcos-Martínez MJ, Valiyeva F, Vivas-Mejía PE. Flores-Colón M, et al. Int J Mol Sci. 2024 Mar 28;25(7):3793. doi: 10.3390/ijms25073793. Int J Mol Sci. 2024. PMID: 38612604 Free PMC article.

145

Integrin αvβ3 and LHRH Receptor Double Directed Nano-Analogue Effective Against Ovarian Cancer in Mice Model.

Qi N, Zhou X, Ma N, Zhang J, Wang Z, Zhang X, Li A. Qi N, et al. Int J Nanomedicine. 2024 Mar 28;19:3071-3086. doi: 10.2147/IJN.S442921. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38562611 Free PMC article.

146

Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes.

Fang CH, Cheng WF, Cheng YF, Lan KL, Lee JM. Fang CH, et al. BMC Cancer. 2024 Mar 28;24(1):395. doi: 10.1186/s12885-024-12101-3. BMC Cancer. 2024. PMID: 38549061 Free PMC article.

147

Drug resistance in ovarian cancer: from mechanism to clinical trial.

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, Tang Q, Li Q, Zhang C, Wang H, Zou D. Wang L, et al. Mol Cancer. 2024 Mar 28;23(1):66. doi: 10.1186/s12943-024-01967-3. Mol Cancer. 2024. PMID: 38539161 Free PMC article. Review.

148

CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.

Zhang Q, Zhang R, Li Y, Yang X. Zhang Q, et al. J Ovarian Res. 2024 Mar 27;17(1):68. doi: 10.1186/s13048-024-01393-5. J Ovarian Res. 2024. PMID: 38539247 Free PMC article.

149

Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.

Xia Y, Wang S, Sun Y, Wang W, Chang S, Zhang Z, Zhao C. Xia Y, et al. Cell Commun Signal. 2024 Mar 27;22(1):194. doi: 10.1186/s12964-024-01585-y. Cell Commun Signal. 2024. PMID: 38539211 Free PMC article.

150

Development and validation of an interpretable model integrating multimodal information for improving ovarian cancer diagnosis.

Xiang H, Xiao Y, Li F, Li C, Liu L, Deng T, Yan C, Zhou F, Wang X, Ou J, Lin Q, Hong R, Huang L, Luo L, Lin H, Lin X, Chen H. Xiang H, et al. Nat Commun. 2024 Mar 27;15(1):2681. doi: 10.1038/s41467-024-46700-2. Nat Commun. 2024. PMID: 38538600 Free PMC article.

151

Metastasis of serous ovarian carcinoma to the breast: a case report and review of the literature.

Dueño S, Stein R, Jamal M, Lewis G, Hew K. Dueño S, et al. J Med Case Rep. 2024 Mar 26;18(1):127. doi: 10.1186/s13256-024-04445-y. J Med Case Rep. 2024. PMID: 38528610 Free PMC article. Review.

152

Patient-reported outcome measures (PROMs) to personalise follow-up care of ovarian cancer: what do patients think? A qualitative interview study.

Seeratan DD, van Schuylenburch RG, van Lonkhuijzen LRCW, Aarts JWM. Seeratan DD, et al. Support Care Cancer. 2024 Mar 26;32(4):247. doi: 10.1007/s00520-024-08436-z. Support Care Cancer. 2024. PMID: 38528152 Free PMC article.

153

Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations.

Liu D, Cao M, Wang H, Cao W, Zheng C, Li Y, Wang Y. Liu D, et al. BMC Med. 2024 Mar 25;22(1):137. doi: 10.1186/s12916-024-03352-9. BMC Med. 2024. PMID: 38528540 Free PMC article.

154

Accuracy of endometrial sampling in the diagnosis of endometrial cancer: a multicenter retrospective analysis of the JAGO-NOGGO.

Alwafai Z, Beck MH, Fazeli S, Gürtler K, Kunz C, Singhartinger J, Trojnarska D, Zocholl D, Krankenberg DJ, Blohmer JU, Sehouli J, Pietzner K. Alwafai Z, et al. BMC Cancer. 2024 Mar 25;24(1):380. doi: 10.1186/s12885-024-12127-7. BMC Cancer. 2024. PMID: 38528468 Free PMC article.

155

Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancers.

Went M, Sud A, Mills C, Hyde A, Culliford R, Law P, Vijayakrishnan J, Gockel I, Maj C, Schumacher J, Palles C, Kaiser M, Houlston R. Went M, et al. Nat Commun. 2024 Mar 25;15(1):2637. doi: 10.1038/s41467-024-46927-z. Nat Commun. 2024. PMID: 38527997 Free PMC article.

156

Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.

Kang J, Na K, Kang H, Cho U, Kwon SY, Hwang S, Lee A. Kang J, et al. PLoS One. 2024 Mar 25;19(3):e0298128. doi: 10.1371/journal.pone.0298128. eCollection 2024. PLoS One. 2024. PMID: 38527014 Free PMC article.

157

Squamous cell carcinoma malignant transformation in mature cystic teratoma of the ovary: a case report and review of the literature.

Jafari-Nozad AM, Jahani N, Nazeri N. Jafari-Nozad AM, et al. J Med Case Rep. 2024 Mar 25;18(1):145. doi: 10.1186/s13256-024-04465-8. J Med Case Rep. 2024. PMID: 38523295 Free PMC article. Review.

158

HSPA8-mediated stability of the CLPP protein regulates mitochondrial autophagy in cisplatin-resistant ovarian cancer cells.

Kou X, Yang X, Zhao Z, Li L. Kou X, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):356-365. doi: 10.3724/abbs.2023246. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38419499 Free PMC article.

159

Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations-A Review.

Choi SY, Choi JH. Choi SY, et al. Medicina (Kaunas). 2024 Mar 21;60(3):516. doi: 10.3390/medicina60030516. Medicina (Kaunas). 2024. PMID: 38541242 Free PMC article. Review.

160

APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer.

Yang S, Du J, Wang W, Zhou D, Xi X. Yang S, et al. BMC Cancer. 2024 Mar 21;24(1):364. doi: 10.1186/s12885-024-12105-z. BMC Cancer. 2024. PMID: 38515073 Free PMC article.

161

Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.

Kuang L, Zhang J, Li Y, Wang Q, Liu J, Zhang B. Kuang L, et al. BMC Womens Health. 2024 Mar 21;24(1):188. doi: 10.1186/s12905-024-03021-2. BMC Womens Health. 2024. PMID: 38515066 Free PMC article.

162

Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.

Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, Skapa P, Capkova L, Kovar M, Prochazka J, Praznovec I, Koblizek V, Taskova A, Tanaka H, Lischke R, Mendez FC, Vachtenheim J Jr, Heinzelmann-Schwarz V, Jacob F, McNeish IA, Halaska MJ, Rob L, Cibula D, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Kasikova L, et al. Nat Commun. 2024 Mar 21;15(1):2528. doi: 10.1038/s41467-024-46873-w. Nat Commun. 2024. PMID: 38514660 Free PMC article.

163

Enhancing precision medicine: a nomogram for predicting platinum resistance in epithelial ovarian cancer.

Li R, Xiong Z, Ma Y, Li Y, Yang Y, Ma S, Ha C. Li R, et al. World J Surg Oncol. 2024 Mar 21;22(1):81. doi: 10.1186/s12957-024-03359-9. World J Surg Oncol. 2024. PMID: 38509620 Free PMC article.

164

Risk-reducing decisions regarding germline BRCA pathogenic variant: focusing on the timing of genetic testing and RRSO.

Abe A, Nomura H, Fusegi A, Yunokawa M, Ueki A, Habano E, Arakawa H, Kaneko K, Minoura Y, Inari H, Ueno T, Kanao H. Abe A, et al. J Med Genet. 2024 Mar 21;61(4):392-398. doi: 10.1136/jmg-2023-109549. J Med Genet. 2024. PMID: 38124001 Free PMC article.

165

Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.

Hu H, Sun C, Chen J, Li Z. Hu H, et al. J Cancer Res Clin Oncol. 2024 Mar 20;150(3):146. doi: 10.1007/s00432-024-05654-0. J Cancer Res Clin Oncol. 2024. PMID: 38509422 Free PMC article. Review.

166

Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China.

Fu K, Li Q, Wang J, Zhang M, Yan X, Li K, Song L, Zhong L, Ma Y, Chen J, Zeng J, Wang D, Shao D, Zhu S, Yin R. Fu K, et al. Sci Rep. 2024 Mar 20;14(1):6702. doi: 10.1038/s41598-024-52707-y. Sci Rep. 2024. PMID: 38509102 Free PMC article.

167

Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.

de Freitas Ribeiro AA, Junior NMC, Dos Santos LL. de Freitas Ribeiro AA, et al. Eur J Med Res. 2024 Mar 20;29(1):187. doi: 10.1186/s40001-024-01767-x. Eur J Med Res. 2024. PMID: 38504328 Free PMC article.

168

Proteomic insight towards key modulating proteins regulated by the aryl hydrocarbon receptor involved in ovarian carcinogenesis and chemoresistance.

Therachiyil L, Peerapen P, Younis SM, Ahmad A, Thongboonkerd V, Uddin S, Korashy HM. Therachiyil L, et al. J Proteomics. 2024 Mar 20;295:105108. doi: 10.1016/j.jprot.2024.105108. Epub 2024 Feb 4. J Proteomics. 2024. PMID: 38316181 Free article.

169

TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.

Hu R, Cao Y, Wang Y, Zhao T, Yang K, Fan M, Guan M, Hou Y, Ying J, Ma X, Deng N, Sun X, Zhang Y, Zhang X. Hu R, et al. Breast Cancer Res. 2024 Mar 19;26(1):48. doi: 10.1186/s13058-024-01802-z. Breast Cancer Res. 2024. PMID: 38504374 Free PMC article.

170

Portulaca oleracea L. polysaccharide inhibits ovarian cancer via inducing ACSL4-dependent ferroptosis.

Xia L, Yang M, Liu Y. Xia L, et al. Aging (Albany NY). 2024 Mar 19;16(6):5108-5122. doi: 10.18632/aging.205608. Epub 2024 Mar 19. Aging (Albany NY). 2024. PMID: 38503553 Free PMC article.

171

The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk.

Zhu J, Zhu H, Zhu Q, Xu SL, Xiao L, Zhang MY, Gao J. Zhu J, et al. Sci Rep. 2024 Mar 18;14(1):6504. doi: 10.1038/s41598-024-57196-7. Sci Rep. 2024. PMID: 38499622 Free PMC article.

172

Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.

Crump LS, Floyd JL, Kuo LW, Post MD, Bickerdike M, O'Neill K, Sompel K, Jordan KR, Corr BR, Marjon N, Woodruff ER, Richer JK, Bitler BG. Crump LS, et al. Cancer Res Commun. 2024 Mar 18;4(3):822-833. doi: 10.1158/2767-9764.CRC-23-0513. Cancer Res Commun. 2024. PMID: 38451784 Free PMC article.

173

Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer.

Karanth S, Osazuwa-Peters OL, Wilson LE, Previs RA, Rahman F, Huang B, Pisu M, Liang M, Ward KC, Schymura MJ, Berchuck A, Akinyemiju TF. Karanth S, et al. Cancer Res Commun. 2024 Mar 18;4(3):811-821. doi: 10.1158/2767-9764.CRC-23-0283. Cancer Res Commun. 2024. PMID: 38441644 Free PMC article.

174

Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.

Zhao M, Gao Y, Yang J, He H, Su M, Wan S, Feng X, Wang H, Cai H. Zhao M, et al. Eur J Med Res. 2024 Mar 17;29(1):179. doi: 10.1186/s40001-024-01666-1. Eur J Med Res. 2024. PMID: 38494480 Free PMC article.

175

Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes.

Xie Y, Ella KM, Gibbs TC, Yohannan ME, Knoepp SM, Balijepalli P, Meier GP, Meier KE. Xie Y, et al. Cells. 2024 Mar 16;13(6):520. doi: 10.3390/cells13060520. Cells. 2024. PMID: 38534364 Free PMC article.

176

The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.

Hagi T, Vangveravong S, Takchi R, Gong Q, Goedegebuure SP, Tiriac H, Van Tine BA, Powell MA, Hawkins WG, Spitzer D. Hagi T, et al. Sci Rep. 2024 Mar 16;14(1):6373. doi: 10.1038/s41598-024-56928-z. Sci Rep. 2024. PMID: 38493257 Free PMC article.

177

Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value.

Hong S, Fu N, Sang S, Ma X, Sun F, Zhang X. Hong S, et al. J Ovarian Res. 2024 Mar 16;17(1):64. doi: 10.1186/s13048-024-01386-4. J Ovarian Res. 2024. PMID: 38493179 Free PMC article.

178

Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.

Feng S, Ding B, Dai Z, Yin H, Ding Y, Liu S, Zhang K, Lin H, Xiao Z, Shen Y. Feng S, et al. J Transl Med. 2024 Mar 15;22(1):280. doi: 10.1186/s12967-024-05085-y. J Transl Med. 2024. PMID: 38491511 Free PMC article.

179

The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.

Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. Chase DM, et al. BMC Womens Health. 2024 Mar 15;24(1):179. doi: 10.1186/s12905-024-02977-5. BMC Womens Health. 2024. PMID: 38491366 Free PMC article.

180

Microfluidic production of amiodarone loaded nanoparticles and application in drug repositioning in ovarian cancer.

Saorin A, Saorin G, Duzagac F, Parisse P, Cao N, Corona G, Cavarzerani E, Rizzolio F. Saorin A, et al. Sci Rep. 2024 Mar 15;14(1):6280. doi: 10.1038/s41598-024-55801-3. Sci Rep. 2024. PMID: 38491077 Free PMC article.

181

Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.

Khoshtinat Nikkhoi S, Yang G, Owji H, Grizotte-Lake M, Cohen RI, Gil Gonzalez L, Massumi M, Hatefi A. Khoshtinat Nikkhoi S, et al. J Immunother Cancer. 2024 Mar 15;12(3):e008295. doi: 10.1136/jitc-2023-008295. J Immunother Cancer. 2024. PMID: 38490714 Free PMC article.

182

The analysis of preoperative or intraoperative factors in predicting the escalation of surgical pathological staging of patients with clinical stage I endometrioid carcinoma: A retrospective clinical study.

Li N, Chen Q, Li B. Li N, et al. Medicine (Baltimore). 2024 Mar 15;103(11):e37465. doi: 10.1097/MD.0000000000037465. Medicine (Baltimore). 2024. PMID: 38489719 Free PMC article.

183

Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.

Mikhael S, Kurdi A, Khoueiry-Zgheib N, Tahtouh R, Nasr R, Hilal G. Mikhael S, et al. PLoS One. 2024 Mar 15;19(3):e0298127. doi: 10.1371/journal.pone.0298127. eCollection 2024. PLoS One. 2024. PMID: 38489280 Free PMC article.

184

Body mass index and risk of cancer in young women.

Dikaiou P, Edqvist J, Lagergren J, Adiels M, Björck L, Rosengren A. Dikaiou P, et al. Sci Rep. 2024 Mar 15;14(1):6245. doi: 10.1038/s41598-024-56899-1. Sci Rep. 2024. PMID: 38485791 Free PMC article.

185

Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.

Li J, Sun Y, Zhi X, Sun Y, Abudousalamu Z, Lin Q, Li B, Yao L, Chen M. Li J, et al. J Ovarian Res. 2024 Mar 14;17(1):61. doi: 10.1186/s13048-024-01384-6. J Ovarian Res. 2024. PMID: 38486335 Free PMC article.

186

Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023.

Korsholm LM, Broecker V, Mirza MR, Rossing M. Korsholm LM, et al. Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139. Acta Oncol. 2024. PMID: 38482597 Free article.

187

Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.

Wang G, Liu X, You Y, Chen S, Chang X, Yang Q. Wang G, et al. J Ovarian Res. 2024 Mar 13;17(1):58. doi: 10.1186/s13048-023-01326-8. J Ovarian Res. 2024. PMID: 38481252 Free PMC article.

188

Mucin-producing tumors of the ovary--preoperative differentiation between metastatic ovarian mucinous carcinoma and primary mucinous malignant tumors.

Cai SQ, Wu MR, Ma XL, Lu JJ, Qiang JW, Guan YY, Zeng MS, Zhou JJ. Cai SQ, et al. J Ovarian Res. 2024 Mar 13;17(1):59. doi: 10.1186/s13048-024-01382-8. J Ovarian Res. 2024. PMID: 38481236 Free PMC article.

189

A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.

Sun Y, Zhang K, Wang T, Zhao S, Gao C, Xue F, Wang Y. Sun Y, et al. Sci Rep. 2024 Mar 13;14(1):6134. doi: 10.1038/s41598-024-56676-0. Sci Rep. 2024. PMID: 38480789 Free PMC article.

190

Identification of the prognostic value of LACTB2 and its correlation with immune infiltrates in ovarian cancer by integrated bioinformatics analyses.

Cao W, Wang C, Zhang Y, Yang J, Luo X, Zhao Y, Wu M, Cheng S, Wang Y. Cao W, et al. Eur J Med Res. 2024 Mar 12;29(1):166. doi: 10.1186/s40001-024-01762-2. Eur J Med Res. 2024. PMID: 38475882 Free PMC article.

191

Survival time prediction in patients with high-grade serous ovarian cancer based on ¹⁸F-FDG PET/CT- derived inter-tumor heterogeneity metrics.

He D, Zhang X, Chang Z, Liu Z, Li B. He D, et al. BMC Cancer. 2024 Mar 12;24(1):337. doi: 10.1186/s12885-024-12087-y. BMC Cancer. 2024. PMID: 38475819 Free PMC article.

192

Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.

Hao L, Boehnke N, Elledge SK, Harzallah NS, Zhao RT, Cai E, Feng YX, Neaher S, Fleming HE, Gupta PB, Hammond PT, Bhatia SN. Hao L, et al. Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307802121. doi: 10.1073/pnas.2307802121. Epub 2024 Mar 4. Proc Natl Acad Sci U S A. 2024. PMID: 38437557 Free PMC article.

193

A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.

Zhu L, Lin Z, Wang K, Gu J, Chen X, Chen R, Wang L, Cheng X. Zhu L, et al. Front Endocrinol (Lausanne). 2024 Mar 11;15:1372413. doi: 10.3389/fendo.2024.1372413. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38529390 Free PMC article.

194

Kynurenine in IDO1^high cancer cell-derived extracellular vesicles promotes angiogenesis by inducing endothelial mitophagy in ovarian cancer.

Ying X, Zheng X, Zhang X, Yin Y, Wang X. Ying X, et al. J Transl Med. 2024 Mar 11;22(1):267. doi: 10.1186/s12967-024-05054-5. J Transl Med. 2024. PMID: 38468343 Free PMC article.

195

ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer.

Nie X, Gao L, Zheng M, Wang S, Wang C, Li X, Liu O, Gou R, Liu J, Lin B. Nie X, et al. BMC Cancer. 2024 Mar 11;24(1):330. doi: 10.1186/s12885-024-11958-8. BMC Cancer. 2024. PMID: 38468232 Free PMC article.

196

Using online search activity for earlier detection of gynaecological malignancy.

Barcroft JF, Yom-Tov E, Lampos V, Ellis LB, Guzman D, Ponce-López V, Bourne T, Cox IJ, Saso S. Barcroft JF, et al. BMC Public Health. 2024 Mar 11;24(1):608. doi: 10.1186/s12889-024-17673-0. BMC Public Health. 2024. PMID: 38462622 Free PMC article.

197

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.

Abujamous L, Soltani A, Al-Thawadi H, Agouni A. Abujamous L, et al. Biomol Biomed. 2024 Mar 11;24(2):230-237. doi: 10.17305/bb.2023.9757. Biomol Biomed. 2024. PMID: 38231530 Free PMC article. Review.

198

Ruptured Ovarian Cystic Teratoma: A Rare Diagnosis, Easily to Be Confused with Peritoneal Carcinomatosis.

Costachescu D, Motofelea AC, Malita D, Birsasteanu F, Ionita I, Motofelea N, Jura CA, Bacila IF, Bacila M, Motoi S. Costachescu D, et al. Medicina (Kaunas). 2024 Mar 10;60(3):460. doi: 10.3390/medicina60030460. Medicina (Kaunas). 2024. PMID: 38541186 Free PMC article.

199

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.

Bailey M, Morand S, Royfman R, Lin L, Singh A, Stanbery L, Walter A, Hamouda D, Nemunaitis J. Bailey M, et al. Int J Mol Sci. 2024 Mar 9;25(6):3173. doi: 10.3390/ijms25063173. Int J Mol Sci. 2024. PMID: 38542143 Free PMC article. Review.

200

Machine learning developed a CD8⁺ exhausted T cells signature for predicting prognosis, immune infiltration and drug sensitivity in ovarian cancer.

Chen R, Zheng Y, Fei C, Ye J, Fei H. Chen R, et al. Sci Rep. 2024 Mar 9;14(1):5794. doi: 10.1038/s41598-024-55919-4. Sci Rep. 2024. PMID: 38461331 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

27,530 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

27,530 results

Results by year